Inventor · disambiguated record
Yariv Mazor
Also filed as: MAZOR YARIV
11 granted patents·12 pending applications·92 citations·filing 2007–2024
89Inventor score
Top patents by PatentIndex Score
23 records- 0195US9527927B2Modified polypeptides for bispecific antibody scaffoldsMEDIMMUNE LLC·Filed 2012·Granted Dec 27, 2016·41 cites·11 claims
- 0293US10457732B2Bispecific binding proteins and uses thereofMEDIMMUNE LLC·Filed 2017·Granted Oct 29, 2019·10 cites·12 claims
- 0392US8067179B2Immunoglobulin librariesGEORGIOU GEORGE·Filed 2007·Granted Nov 29, 2011·15 cites·44 claims
- 0491US8426187B2Immunoglobulin librariesGEORGIOU GEORGE·Filed 2011·Granted Apr 23, 2013·10 cites·10 claims
- 0589USRE49908EBispecific binding proteins and uses thereofMEDIMMUNE LLC·Filed 2021·Granted Apr 9, 2024·1 cites·43 claims
- 0689US11279759B2Bispecific binding proteins and uses thereofMEDIMMUNE LLC·Filed 2019·Granted Mar 22, 2022·4 cites·19 claims
- 0787US8043621B2Recombinant fusion protein and polynucleotide construct for immunotoxin productionUNIV RAMOT·Filed 2008·Granted Oct 25, 2011·10 cites·16 claims
- 0887US2025074986A1Bispecific binding proteins and uses thereofMEDIMMUNE LLC·Filed 2024·Application pending·0 cites
- 0975US9244070B2Immunoglobulin librariesRES DEV FOUNDATION·Filed 2013·Granted Jan 26, 2016·1 cites·44 claims
- 1075US2022251204A1Bispecific binding proteins and uses thereofMEDIMMUNE LLC·Filed 2021·Application pending·0 cites
- 1172US2024360226A1Antibody molecules and conjugatesASTRAZENECA AB·Filed 2024·Application pending·0 cites
- 1271US12065496B2Antibody molecules and conjugatesASTRAZENECA AB·Filed 2022·Granted Aug 20, 2024·0 cites·27 claims
- 1365US2025115678A1T cell binding compositions and methodsASTRAZENECA AB·Filed 2024·Application pending·0 cites
- 1462US2024417468A1Trispecific Engineered AntibodiesMEDIMMUNE LLC·Filed 2024·Application pending·0 cites
- 1562US2025011426A1Engineered AntibodiesMEDIMMUNE LLC·Filed 2024·Application pending·0 cites
- 1662US2024417467A1Bispecific Engineered AntibodiesMEDIMMUNE LLC·Filed 2024·Application pending·0 cites
- 1761US2025019438A1Optimized CD3 Antigen Binding DomainsMEDIMMUNE LLC·Filed 2024·Application pending·0 cites
- 1861US2025059295A1Steap2 directed t-cell engagers and compositions thereofMEDIMMUNE LLC·Filed 2024·Application pending·0 cites
- 1960US11939382B2Bispecific PD-1 and TIGIT binding proteins and uses thereofMEDIMMUNE LLC·Filed 2022·Granted Mar 26, 2024·0 cites·20 claims
- 2054US2025121104A1Egfr-cmet-targeted compounds and uses thereofFUSION PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2150US2022332818A1Bispecific antibody targeting pd-1 and tim-3MEDIMMUNE LLC·Filed 2022·Application pending·0 cites
- 2249US8329183B2Recombinant fusion protein and polynucleotide construct for immunotoxin productionBENHAR ITAI·Filed 2011·Granted Dec 11, 2012·0 cites·20 claims
- 2338US2011053803A1Methods for creating antibody librariesGE XIN·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yariv Mazor files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →